Damien Gruson

#Testing #Medicine #Health #Laboratory #Biomarker

[Damien Gruson @DAMGRU]

@_EFLM

[EFLM @_EFLM]

📢 The latest edition of the EFLM EuroLabNews (May-June 2026) is officially available.🔬✨

Read the new issue of EuroLabNews here! 👇
🔗https://t.co/N4ZAySdk2D

#EFLM #EuroLabNews #LaboratoryMedicine #ClinicalChemistry

[Damien Gruson @DAMGRU]

#Biomarker #HeartFailure @LabMedDiscovery

[LabMed Discovery @LabMedDiscovery]

New study in LMD: ABEI-based CA125 immunoassay evaluated in 108 HFrEF patients.
✅Strong agreement with reference method
✅Higher CA125 → lower LVEF, higher galectin-3/sST2, worse survival
ABEI-based CA125 may aid risk assessment & treatment monitoring in heart failure
#Heart

[Damien Gruson @DAMGRU]

#VitaminD deficiency, more than a metabolic issue. Emerging evidence suggests a link between low vitamin D and uterine fibroids.
#WomenHealth #LaboratoryMedicine
https://t.co/q1caqC0uMe

[Global Heart Hub @GlobalHeartHub]

Hypertension (high blood pressure) is often called “the silent condition” because you may not feel it, but your heart does. 📈 #Hypertension puts extra strain on the heart, which over time can lead to heart failure.

Hypertension is a leading cause of heart failure; they are connected conditions 🔗.

Know your blood pressure numbers and encourage someone you care about to do the same.

May is Heart Failure Awareness Month ❤️, led by the Heart Failure Patient Network at @GlobalHeartHub — the international alliance of heart patient organisations. 🌐 Learn more: https://t.co/FXSTJrckYx It’s also #MayMeasurementMonth, a global blood pressure screening awareness event.

#HeartFailure #ConnectedCare #HeartFailureAwareness #hypertension #bloodpressure #MMM

[European Society of Cardiology Journals @ESC_Journals]

🆕 Optimal lifelong roadmap post-ACS
A new clinical consensus statement from the European association of preventive cardiology outlines a structured, lifelong care pathway after ACS.
From acute care ➡️ long-term prevention
Bridging gaps, reducing disparities, improving outcomes.
https://t.co/7tqYoyi2KB

@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic #cvprev #EJPC

[JAMA @JAMA_current]

💬 Viewpoint by Canio Martinelli, MD, MSc, Vincenzo Carnevale, PhD, MSc, Alfredo Ercoli, MD, PhD, and Antonio Giordano, MD, PhD: #AI yields higher empathy scores in text assessments but cannot perform clinical examination or patient care. Clinician oversight and presence remain essential in #Medicine.

https://t.co/vo11BLhb6S

[Heart Failure Policy Network @HFPolicyNetwork]

Personalised care and empowered citizens are key to improving #HeartFailure outcomes.

This #EuropeanPatientsRightsDay, we call for policy to ensure access to high-quality HF care for all. https://t.co/J1NfzRWIoy

[Damien Gruson @DAMGRU]

H + A = B
Human + Artificial = Beneficial Intelligence
AI won’t improve patient outcomes alone.
--> Value = Human judgment + AI power

From automation → augmentation
From data → decision

🧠 AI informs
❤️ Humans decide
#AI #LabMedicine #Healthcare

https://t.co/4hSCFdnkpn

[World Health Organization (WHO) @WHO]

Tips to prevent anaemia:

Choose foods rich in iron, folate, vitamin A and B12.

[EFLM @_EFLM]

🔬✨ Global MedLab Week 2026 organized by the #IFCC is here! ✨🔬

📸🎥🎙️ Submit your photo, video, or audio and be part of a global celebration of science, dedication, and impact here: https://t.co/Jh15fEcWXJ

🔗 Learn more: https://t.co/1GRCAy5rq8

#GlobalMedLabWeek #GMLW2026

[ClinChemINFO @ClinChemINFO]

Pre-analytical stability of blood samples transported by drone versus ground: a pilot study https://t.co/K5ykCtHsFK #LabMedX

[Damien Gruson @DAMGRU]

#Webinar @IFClinChem

[IFCC&LM @IFClinChem]

Next: #IFCCLiveWebinar on: “The Pros and Cons of POCT: a double-edged sword”

Date: 15 April 2026

Certificate available for all registrants

Register here: https://t.co/5BXPaxm2Jj

#IFCCLiveWebinars #webinar #ifcc #ClinicalChemistry #ifclinchem #LaboratoryMedicine #Laboratory

[Damien Gruson @DAMGRU]

AI alone is not enough.
The future lies in #BeneficialIntelligence = Human + Artificial Intelligence
- Technology must be guided by purpose, ethics & empathy
- Outcomes > outputs
- Humans augmented, not replaced
#AI #LabMedicine #Value @IFClinChem
https://t.co/4hSCFdnkpn

[EFLM @_EFLM]

2nd issue of EuroLabNews!
Inside you will find:
🎯 The EFLM strategic plan 2026–2027
🏆️ Reports and insights from this year’s EFLM research grants winners
⚖️ Key updates and initiatives from the Committee:Harmonization
🧠 The YS corner with exciting news
https://t.co/DddjvLzgOV

[Damien Gruson @DAMGRU]

#Diabetes @NEJM

[NEJM @NEJM]

𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗴𝗼𝗻𝗶𝘀𝘁𝘀 𝗼𝗻 𝗚𝗹𝘆𝗰𝗮𝘁𝗲𝗱 𝗛𝗲𝗺𝗼𝗴𝗹𝗼𝗯𝗶𝗻 𝗟𝗲𝘃𝗲𝗹𝘀

Randomized, placebo-controlled trials of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong evidence to support their use — in fact, they have presaged a mini-revolution in how type 2 diabetes is managed. 👉 https://t.co/D0XSLv7U8n

Tirzepatide was the first dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonist approved for the treatment of type 2 diabetes on the basis of the SURPASS-1 (Tirzepatide [LY3298176] in Participants with Type 2 Diabetes Not Controlled with Diet and Exercise Alone) trial, a randomized, placebo-controlled trial of tirzepatide (administered in weekly doses of 5 mg, 10 mg, or 15 mg) paired with metformin for treatment of type 2 diabetes (seen in figure). Tirzepatide reduced glycated hemoglobin levels by as much as 2 percentage points and was superior to placebo at all dose levels. At 40 weeks, nearly 90% of participants had glycated hemoglobin levels of less than 7.0%, a change that was associated with profound weight loss.

Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @TuftsMedSchool and the Maine Medical Center Institute for Research: https://t.co/D0XSLv7U8n

[Damien Gruson @DAMGRU]

#Lipid Guidelines @JAMA_current
https://t.co/nsdiiVV5V4

[Global Heart Hub @GlobalHeartHub]

Last chance to register ⌛️ Join our upcoming Empower webinar: Dealing with Dismissal 💜

Too many people still experience being dismissed or unheard in healthcare – particularly women and underserved communities.
In this session, Global Heart Hub, together with our Affiliate @heartsistasinc, will explore practical ways to recognise, navigate and respond to #dismissal across the patient journey.

💬 What to expect:
• How to prepare for medical appointments to reduce the likelihood of dismissal.
• Strategies to address dismissal.
• Practical measures to recover from the feeling of being dismissed.

Join us for a powerful and practical conversation focused on strengthening patient confidence, voice and advocacy.

👉 Register now: https://t.co/wWpk41HPTN

#PatientVoices #HealthEquity #Empower #GlobalHeartHub #CardiovascularHealth

[Damien Gruson @DAMGRU]

#LaboratoryMedicine is becoming a #Health Intelligence Hub.
AI, decentralization, and precision medicine are transforming diagnostics from:
❌ reactive → ✅ predictive
❌ data → ✅ insights
❌ volume → ✅ outcomes
Trends 2026, follow the link ;-) :
https://t.co/pIgvos5kLr

[JAMA @JAMA_current]

📊 JAMA Clinical Guidelines Synopsis: The 2025 ACC/AHA guideline recommends home and office #BloodPressure monitoring to confirm diagnosis and titrate medications, with a target blood pressure of <130/80 mm Hg for most adults.

https://t.co/WKRTf0icSx

[Damien Gruson @DAMGRU]

The SFBC Symposium 2026 will highlight innovation in laboratory medicine and cardiovascular health, a key opportunity to connect, learn, and shape the future of diagnostics.

📍 Bordeaux | 📅 December 4, 2026
👉 Join us: https://t.co/WyFEwKWOyA
#LaboratoryMedicine #Cardiology